10-KPeriod: FY2019

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2019

Filed February 13, 2020For Securities:VRTX

Summary

Vertex Pharmaceuticals reported strong revenue growth in 2019, driven primarily by its suite of cystic fibrosis (CF) treatments, particularly the newly approved TRIKAFTA. The company's strategic focus remains on advancing its CF pipeline and expanding treatment options for patients, aiming to cover up to 90% of the CF population. Beyond CF, Vertex is actively investing in and diversifying its pipeline with promising early-stage programs in areas such as alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, sickle cell disease, beta-thalassemia, type 1 diabetes, and muscular dystrophies. Financially, Vertex demonstrated robust performance with increasing product revenues and controlled expense growth, leading to significant operating margins. The company also made substantial strategic investments in 2019 through acquisitions, notably Semma Therapeutics for type 1 diabetes and Exonics for genetic therapies. With a strong cash position and clear revenue drivers in its CF franchise, Vertex is well-positioned for continued growth and pipeline advancement.

Financial Highlights

53 data points
Beta

Revenue

$4.16B

86.8% Gross Margin

Net Income

$1.18B

28.3% Net Margin

EPS (Diluted)

$4.51

Total Assets

$8.32B

Cash & Equivalents

$3.11B

Free Cash Flow

$1.49B

Financial Statements
Beta
Revenue$4.16B
Cost of Revenue$547.80M
Gross Profit$3.62B
R&D Expenses$1.75B
SG&A Expenses$658.50M
Operating Expenses$2.97B
Operating Income$1.20B
Interest Expense$58.50M
Net Income$1.18B
EPS (Basic)$4.58
EPS (Diluted)$4.51
Shares Outstanding (Basic)256.70M
Shares Outstanding (Diluted)260.70M

Key Highlights

  • 1Strong revenue growth in 2019, driven by a significant increase in product revenues, largely from existing and newly approved cystic fibrosis (CF) medicines.
  • 2FDA approval of TRIKAFTA in October 2019 for CF patients aged 12 and older with at least one F508del mutation, expanding treatment eligibility and addressing a key unmet need.
  • 3Active pipeline expansion beyond CF, with notable progress in early-stage programs for alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, and gene/cell therapies for sickle cell disease, beta-thalassemia, type 1 diabetes, and muscular dystrophies.
  • 4Significant strategic acquisitions in 2019, including Semma Therapeutics ($950 million) for type 1 diabetes cell therapies and Exonics ($245 million upfront) for genetic therapies for neuromuscular diseases, bolstering the company's diversification strategy.
  • 5Robust financial health demonstrated by substantial cash reserves ($3.8 billion as of December 31, 2019) and increasing operating income, reflecting successful commercialization and efficient operations.
  • 6Continued focus on obtaining ex-U.S. regulatory approvals and reimbursement for key products, including the submission of a Marketing Authorization Application for TRIKAFTA to the EMA.
  • 7Management expressed confidence in continued revenue growth in 2020, supported by TRIKAFTA's launch, label expansions, and broader market access for its CF portfolio.

Frequently Asked Questions

Vertex's primary revenue drivers are its cystic fibrosis (CF) medicines, including KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI, and the recently approved TRIKAFTA. The company acknowledges the concentration risk and is actively mitigating it by investing heavily in R&D and business development to diversify its pipeline with potential therapies for other serious diseases like alpha-1 antitrypsin deficiency, kidney diseases, pain, and rare genetic disorders.

The FDA approval of TRIKAFTA in October 2019 is highly significant as it is a triple-combination therapy that expands treatment eligibility for CF patients in the U.S. by approximately 6,000. Vertex expects TRIKAFTA revenues to increase significantly in 2020 due to its broader applicability and potential to drive patient switches from older therapies. The company is also pursuing ex-U.S. approvals, including a submission to the EMA, and is evaluating its use in younger age groups.

Vertex is actively diversifying its business through internal research and strategic acquisitions. In 2019, the company made significant acquisitions, including Semma Therapeutics for type 1 diabetes cell therapy and Exonics for genetic therapies for neuromuscular diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1. The company also has ongoing clinical development for alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and pain.

Vertex reported a strong financial position as of December 31, 2019, with $3.8 billion in cash, cash equivalents, and marketable securities. The company generated significant operating income and successfully managed its expenses. It has a $500 million revolving credit facility available and plans to fund its operations and R&D through existing cash flow and its current liquidity. The company also has an ongoing share repurchase program.